As of today, PharSafer will be using the latest version of Oracle Argus Cloud to provide the highest standard of Pharmacovigilance services to our clients.
Oracle Argus Cloud is an industry-leading solution for processing, analysing, and reporting adverse event cases originating in pre- and post-market drugs, biologics, vaccines, devices, and combination products. By extending its use of Oracle Argus Cloud, PharSafer will be better equipped to provide optimised multivigilance services within a multi-tenant ICH E2B R3 XML compliant database. This works for our diverse, global client base.
Running on Oracle Cloud infrastructure, Argus will provide a scalable and secure environment, with assured high availability and 24/7 support. The platform will also provide PharSafer the opportunity to integrate Artificial Intelligence (AI) and Machine Learning (ML) to further automate and improve safety processes, create new opportunities, and evolve with the needs of the industry. PharSafer will also be able to expand services to help other organisations to set up and maintain their own Argus system, and develop additional tools and applications to support multivigilance services. Altogether, providing PharSafer with the most up-to-date global safety technology to help support our compliance goals, as true experts in post marketing drug safety.
In addition to this, PharSafer will also join the recently formed Oracle Health Sciences Safety Consortium – where we will help shape the future of Oracle Argus and other Oracle Health Sciences Safety solutions, as well as collaborate with industry peers to advance drug safety.
“PharSafer is dedicated to providing quality focused pharmacovigilance and medical services around the globe. We are confident in the ability of Oracle Argus Cloud to help us deliver on this promise with the highest levels of compliance and performance — where and when it’s needed and where it matters.”
For more information on the partnership between PharSafer and Oracle please contact:
+44 (0)1483 212155
Oracle Corporate Communications
650 784 7901
+44 (0) 207 067 0274